Genentech, a member of the Roche Group (OTC: RHHBY), announced data from the positive, pivotal Phase III OAK study of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy Regardless of PD-L1 Status in a Specific Type of Lung Cancer in Phase III StudyOctober 9, 2016 2:15 AM Clovis Oncology (CLVS) Announces Presentation of Encouraging Efficacy, Safety Data on Rucaparib in BRCA Ovarian CancerOctober 7, 2016 8:46 AM Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO CongressOctober 7, 2016 8:45 AM Exelixis (EXEL) Announces Presentation of Cobimetinib, Vemurafenib, Atezolizumab Combo Phase 1b Data in BRAF V600October 7, 2016 7:38 AM Exelixis (EXEL) Announces Encouraging Cabozantinib Combo Phase 1 Data in Genitourinary TumorsOctober 7, 2016 7:36 AM Kite Pharma (KITE) Commences KTE-C19 Combo Phase 1b/2 Combination Study in DLBCL (RHHBY)October 6, 2016 8:31 AM